AUSTIN, Texas, Oct. 5, 2020 /PRNewswire/ -- Aeglea
BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology
company developing a new generation of human enzyme therapeutics as
innovative solutions for rare and other high-burden diseases, today
announced the presentation of a poster on the misdiagnosis of
Arginase 1 Deficiency (ARG1-D) as Hereditary Spastic Paraplegia at
the joint 49th Child Neurology Society Annual
Meeting/16th International Child Neurology Congress
(CNS/ICNA). Additionally, the Company will give a poster
presentation on the development of ACN00177, a novel engineered
human enzyme therapy being investigated for the treatment of
Homocystinuria, at the American Society of Human Genetics (ASHG)
Virtual Meeting 2020.
CNS/ICNA Presentation Details
- Title: Arginase-1 Deficiency (ARG1-D) Masquerading as
Hereditary Spastic Paraplegia: Implications for Diagnostic
Testing
- Poster Number: 510
- Date: October 12-23,
2020
- Location: https://icnapedia.org/congress/icnc2020
ASHG Presentation Details
- Title: Development of a Novel Human Engineered Enzyme
(ACN00177) for the Treatment of Homocystinuria
- Poster Number: 3151
- Session: 208 – Mendelian Phenotypes
- Date: October 27-30,
2020
- Location:
https://www.abstractsonline.com/pp8/#!/9070/presentation/2479
The posters will be available for download on the Presentations
& Events section of the Company's website.
About Aeglea BioTherapeutics
Aeglea BioTherapeutics is a clinical-stage biotechnology company
redefining the potential of human enzyme therapeutics to benefit
people with rare and other high burden diseases. Aeglea's lead
product candidate, pegzilarginase, is in a pivotal Phase 3 trial
for the treatment of Arginase 1 Deficiency and has received both
Rare Pediatric Disease and Breakthrough Therapy Designations. The
Company received approval of its Clinical Trial Application (CTA)
for ACN00177 for the treatment of Homocystinuria by the
United Kingdom's Medicines and
Healthcare Products Regulatory Agency (MHRA). Aeglea has an active
discovery platform, with the most advanced program for Cystinuria.
For more information, please visit http://aegleabio.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aeglea-biotherapeutics-announces-presentations-on-arginase-1-deficiency-and-homocystinuria-programs-at-two-upcoming-virtual-medical-meetings-301145824.html
SOURCE Aeglea Biotherapuetics, Inc.